We strongly encourage other research groups to validate our findings and are in favor of clinical studies involving patients as only these will ultimately prove the true value of BRD4, EZH2 and TOP2A inhibitors in the MPNST setting. The gene discussed is TOP2A; the disease is malignant peripheral nerve sheath tumor.